Portfolio Manager

Biotech Stocks: Sector Outlook and Top Picks

ZymoGenetics is certainly undervalued right now. The total market cap is less than the value of their approved drug, Recothrom, much less their pipeline. Their team has now developed seven approved drugs. If you think about the total number of new drugs approved in a given year, seven drugs is a pretty impressive number.

BioMarin is also an excellent company, but as far as I can tell it is not quite as grossly undervalued as ZymoGenetics.